Braveheart Investment Share Price (BRH)

Share Name Share Symbol Market Type Share ISIN Share Description
Braveheart Investment Group Plc LSE:BRH London Ordinary Share GB00B13XV322 ORD 2P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 13.25 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
12.50 14.00 13.25 13.25 13.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.82 1.49 5.51 2.4 4
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX
Related Shares
Scottish Mortgage Invest... (SMT), F&c Investment (FCIT), Tiger Resource (TIR), Energiser Investments (ENGI)

Braveheart Investment (BRH) Latest News

Braveheart Investment News

Date Time Source Headline
08/7/201912:09ALNCBraveheart Takes Third Of Pharm2Farm, Mulls Lifting Stake To 54%
08/7/201907:37ALNCFAlliance News Flash Headline
08/7/201907:00UKREGBraveheart Investment Group plc Investment in Pharm2Farm Limited
07/6/201911:13ALNCBraveheart Now Has Five Strategic Investments; Results Likely Delayed
07/6/201907:00UKREGBraveheart Investment Group plc Update to the Market
16/4/201913:20ALNCBraveheart Investment Divests Stake In Subsidiary For GBP110,000
16/4/201907:00UKREGBraveheart Investment Group plc Disposal of Viking Fund Managers Limited
12/2/201910:25UKREGRemote Monitored Systems PLC Holding(s) in Company
31/1/201917:17UKREGRemote Monitored Systems PLC Holding(s) in Company
13/12/201810:33ALNCBraveheart Investment In Talks Over Fund Management Division Sale
More Braveheart Investment News
Braveheart Investment Takeover Rumours

Braveheart Investment (BRH) Share Charts

1 Year Braveheart Investment Chart

1 Year Braveheart Investment Chart

1 Month Braveheart Investment Chart

1 Month Braveheart Investment Chart

Intraday Braveheart Investment Chart

Intraday Braveheart Investment Chart

Braveheart Investment (BRH) Discussions and Chat

Braveheart Investment Forums and Chat

Date Time Title Posts
19/7/201910:55Braveheart Investment Group 2012119
09/2/201212:31BRAVEHEART: PURE VALUE36
09/2/201211:08BRAVEHEART INV GROUP ;;;; Uni Funds23

Add a New Thread

Braveheart Investment (BRH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Braveheart Investment trades in real-time

Braveheart Investment (BRH) Top Chat Posts

DateSubject
23/7/2019
09:20		Braveheart Investment Daily Update: Braveheart Investment Group Plc is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker BRH. The last closing price for Braveheart Investment was 13.25p.
Braveheart Investment Group Plc has a 4 week average price of 9p and a 12 week average price of 8.25p.
The 1 year high share price is 19p while the 1 year low share price is currently 8.25p.
There are currently 27,082,565 shares in issue and the average daily traded volume is 61,185 shares. The market capitalisation of Braveheart Investment Group Plc is £3,588,439.86.
Read Full Thread
Reply
02/9/2018
17:33		hughsey1995: Braveheart PLC Share price: 16p Market Cap: £4.33m Fund management business and investment group, holding significant equity stakes in 3 businesses: Kirkstall Ltd, Paraytec Ltd and Gyrometric Ltd. P/L Account - Business highly profitable and cash generative from its fund management business, as well as profit recognised from changes to the fair value of its investments - Trevor Brown very successfully streamlined business - reducing operating costs from £829k in 2017 to £486k in 2018. TB will continue to tightly manage costs as business grows. - £1.492m profit in 2018, up from £779k in 2017 Balance Sheet - Net assets at 2018 year end of £4m - £1.1m cash - Minimal receivables and no material debt Major Shareholders - Trevor Brown, CEO 29.82% - Adam Norris, former Hargreaves Landsdown director, 19.1% - DC Thompson Ltd 8.34% - Major Shareholders hold 66%, free float very small. Fund Management Business - "£71m of funds under management across various regional and national funds... Braveheart also serves the investment appetites of high net worth individuals (HNWs), family offices, institutional investors and public sector organisations spanning the UK and Europe" - Generated £820k revenue in 2018, and 340k profit after all costs for the entire group - Many investment companies burn cash, by incurring PLC costs, without generating any revenues, whilst they wait for their investments to mature. Braveheart is different in that it is generating cash and profits through its fund management business, and so is accumulating cash, to either fund new investments or pay dividends, whilst giving the investments a chance to grow. There is no hurry to exit investments quickly to generate cash, allowing them to grow and maximise value to Braveheart. - Announced on 16th July that Braveheart is in detailed talks with a “large UK financial organisation” to launch a new fund, funded 40% by the financial organisation and 60% by other investors. - New fund expected to be ready to invest before end of 2018. TB confirmed to me on 31/8 that these timings are still on track so I would expect a further update imminently detailing who the financial organisation is and size of the new fund etc. Kirkstall - “Sells products for in vitro cell culture and operates in a worldwide market sector that is projected to grow by 38% annually” - Achieved 35% sales growth in 2017 with own technical staff. SIGNIFICANTLY signed worldwide distribution and marketing agreement with Lonza, one of the world's leading bioscience companies - “This agreement... provides technical validation..., enhancing the company's credibility, but also gives it much greater access to worldwide markets. Lonza has 600 sales staff operating in USA, which is the world's major market for in vitro cell culture and as a result Kirkstall anticipates accelerated growth in its product sales in 2018” - “Recent successes in the USA have been sales to MIT (Massachusetts Institute of Technology) in Boston which is the centre appointed by US National Institute of Health to validate the emerging 'organ on a chip' technologies. The MIT scientists using Kirkstall products are recognised as key opinion leaders in the field.” - “Kirkstall works with universities to develop applications for its products and its user base has grown from 70 to over 90 in the last 12 months. This will increase in 2018 with the award of €4.7million EU Grant to a consortium...” - I am expecting the Lonza marketing and distribution agreement to have seen sales increase massively, which should be confirmed within the interim results in October/November, with projections of further accelerating sales. - My expectation is that at some point Lonza will buyout Kirkstall Ltd. The Kirkstall directors in September 2017 put a valuation on Kirkstall at £5.6m, prior to a potential fundraise, which in the end was cancelled because the business instead signed the distribution agreement with Lonza, and therefore had no need to raise the money to hire sales staff, grow sales etc. I would expect the buyout to be at a price significantly higher than £5.6m given expected growth, perhaps somewhere in the region of £15m-£20m, which would value Braveheart’s stake at £5.6m-£7.5m, though this is obviously highly speculative. Gyrometric - “developed a patent protected system of hardware and software to accurately monitor the vibrations in rotating shafts. Warnings generated by this system help prevent expensive and untimely breakdowns in industry and transport” - “Sales of marine drive monitoring systems continued to expand during the year. The order for the 60th system was taken and commitments for 2018 indicate a continuing acceleration. Feedback from sales agents has confirmed a market opportunity for monitoring additional engine and drive parameters that will broaden the marine market for Gyrometric.” - “launching a new digitisation product at the SMM Ship Technology exhibition in Hamburg – 4th-7th September”. The leading international maritime trade fair”. - Technology tested on a “7 Megawatt wind turbine nacelle at the ORE Catapult test facility in Blyth, Northumberland. The new system, the first for Gyrometric in wind turbines, incorporates world-leading technology for monitoring bearing run out. This technology has particular advantages in wind turbines because of its inherent effectiveness at low turning speeds”. - Huge opportunity to expand into offshore wind turbine market. Results from ORE Catapult test facility extremely positive, so expect Gyrometric to be in discussions with Wind Turbine Manufacturers at present. Nigel Burton of AERO suggested these discussions are ongoing and contracts are expected imminently. Ultimate vision could be to see Gyrometric’s technology fitted onto all new wind turbines at the manufacturing stage, a massive opportunity for Gyrometric, offering a product which could have huge efficiency and cost saving benefits to wind turbine operators. - There is multi billion pound investment into offshore wind at present, and this is expected to continue into the foreseeable future. This is a growing, and potentially highly profitable, market for Gyrometric. - Patent protected technology, and Gyrometric are continually building their IP portfolio. Strat Aero PLC - Braveheart recently announced that it is to sell some of its Gyrometric shares in exchange for a 7% equity stake in Strat Aero PLC. - Braveheart will retain an 18% equity stake in Gyrometric, whilst AERO will hold a controlling stake in the business. - Alongside Gyrometric, AERO runs Geocurve, a business focused upon “providing survey and inspection services using a diverse range of technologies including UAVs, as well as ground- and water-based survey equipment” - Geocurve has begun working with blue chip clients, such as AECOM, and is expected to sign agreements with a growing number of such clients. - Historically business has been loss making thanks to low revenue and high costs. Trevor Brown and Nigel Burton have replaced the old board, with Trevor Brown taking close to a 30% equity stake, and they have reviewed the whole business and slashed operating costs, whilst growing the business. Interim results to be released in September should show growing revenues, and significantly reduced costs. Nigel Burton has said that the company has no expectation of any further placings for plc costs, suggesting that the business is running much closer to being cash break even, or cash generative. With this, and the likelihood of a growing number of clients for both the Geocurve and Gyrometric businesses, I expect the financial performance to show a massive improvement in the current year and beyond, and for the share price to appreciate accordingly, with the current £3.4m market cap pricing in very little potential for these two businesses. Paraytec - “Paraytec is a UK based scientific instrument company that developed the award winning ActiPix™ brand of ultra-violet (UV) area imaging detectors” - “Two main licensees - Malvern Panalytical Ltd and Pion Inc. Concurrently, the company commenced two, key grant funded, R&D projects to develop new product lines for the future… The business is now profitable and cash positive” - “The first R&D project is in Paraytec's traditional market of research instrumentation for the biopharmaceutical sector. In this project, Paraytec is a key member of a consortium including Malvern Panalytical, GSK, Medimmune, Fujifilm Diosynth Biotechnologies and others.” - “The second R&D project is aimed at developing a new point of care diagnostic device for cancer detection and monitoring. Initially this is focussed on bladder cancer, but the technology should be applicable to detecting other cancers… Paraytec hopes to develop technology which will surpass the currently available tests and thus offer considerable cost savings to the healthcare systems worldwide as well as improving the patient experience and outcomes. Preliminary results have been highly promising.” - “Engaged an adviser to raise £4 million of equity fundraising in order to fund the further development, regulatory approval and commercialisation of its innovative urine test for the detection and monitoring of bladder cancer” - “'Paraytec's bladder cancer test shows excellent results in the laboratory and, once clinical trials are successfully completed, it will address a significant clinical need for a simple and non-invasive test for detecting and monitoring bladder cancer. The funds will be used to complete the development programme and conduct the clinical study required to obtain the necessary regulatory approvals and commercialise the test.” Dividend - At 31st March 2018, Braveheart had £1.13m in cash. Given profitable nature of the fund management business, this should have grown to about £1.3m by the interim results, and around £1.5m by the current year end. Presently, the business has a share premium account on its balance sheet, which is a non-distributable reserve, and so the company cannot pay dividends from it. However, Braveheart applied on the 19th July to cancel this share premium account to allow it to pay dividends, a process which is expected to be completed 6-8 weeks after application, so expect confirmation that this is completed in September. - Given Braveheart’s cash balance, and consistent profitability of the fund management business, the company could comfortably pay an annual dividend that paid over 5% yield based on the current market, and then pay potentially very large special dividends as and when the business exits its investments. Legacy Investments - “In addition to our three strategic investments we have investments in a further 12 companies that were made by Braveheart from 2002 until the summer of 2015” - Whilst none of these are very large equity stakes, or ever likely to be worth massive amounts of money, it is very possible that some of these investments prove successful, and yield a healthy return to Braveheart at some point in the future. For example in September 2016, Braveheart completed the sale of an equity stake of about 5% of mLED Limited for £367,000, resulting in a profit to the group of £271,000. Perhaps the most likely legacy investment to provide such a surprise profit in the future is a 2.2% equity stake in Dimensional Imaging Limited (Di4D), a world leading facial performance capture company that has been recently working on a number of high profile Hollywood movies. Outlook The share price of Braveheart is little changed in the last couple of years, despite all areas of the business making significant progress. The future of the Braveheart investment group looks extremely bright, and I expect a significant rerate of the company’s share price, initially to around 30p (88% upside from the current price), but with the potential for much higher in the future, given the potential of their portfolio companies. I expect this rerate to begin imminently, thanks to a number of pieces of news flow that are due in the coming months: - Interim Results: expect a detailed operational update on the 3 investments, and the results to show the continued profitability of the fund management business, and a growing cash pile. Likely the most exciting item will be the Kirkstall operational update, which will be the first time we have had an update on the business’ growth since it signed the worldwide marketing and distribution agreement with Lonza – this could be extremely positive and really show just how much potential Kirkstall has under the guidance of Lonza. - Paraytec – Completion of the proposed fundraising, which alone should see a significant uplift in the value of Braveheart’s stake. I think this is certainly due before the end of 2018. We know that Paraytec is profitable and cash generative; interim results will hopefully talk of continued success through the 2 licenses which it has. We are then also due an update on the development and testing of its bladder cancer detector, and time scales for the development and commercialisation of this technology going forwards. - Gyrometric and Geocurve – Per recent interview by Nigel Burton, very significant contract wins are expected for Gyrometric and Geocurve imminently. Geocurve winning a big contract with a blue chip client like AECOM, or Gyrometric getting a contract with a big wind turbine manufacturer, could be transformational for Braveheart, through its direct investment into Gyrometric, and its equity stake in Strat Aero PLC. News of such wins could come anytime, and are a very genuine possibility before the end of 2018. - Fund Management Business – the new fund is expected to be ready to invest prior to the end of 2018. I would therefore expect a further update on this in September/October. I expect this fund to be of very material size to Braveheart, and could begin adding significant profits within the current financial year. If the fund is £50m+, or is with a very big name financial organisation, or there is any suggestion that further new funds could follow, and this could be massive news for Braveheart. - Completion of the share premium account reduction is expected in September. Braveheart could decide to begin its policy of paying dividends by distributing some of its excess cash as a special dividend with its interim results, otherwise expect the first dividend with the year-end accounts, or a special dividend on any sale, or partial sale, or an investment.
Read Full Thread
Follow
Reply
09/1/2017
22:04		swizz: bf, welcome aboard and good to have another poster, unfortunately TB is not at his best during media interviews, which is in complete contrast when he is one to one, the turn around since TB took the reigns is seriously impressive and bodes well for the future, there is some great things happening at Kirkstall, Paraytec, DI4D, Pyreos, Gyrometric, Viking, Vascular Flow, with the added bonus that everyone of them is producing and generating revenue, .....GL S Braveheart Investment keeping the momentum going INVESTMENT OVERVIEW: BRH THE BIG PICTURE Braveheart seeks to back nascent technology companies and work closely with their boards It is hard sometimes to value an investment company like Braveheart Investment Group PLC (LON:BRH), which plays the long game, backing promising technology businesses. Then, along comes a “value realisation” moment, as they call it in the trade, and things get a bit clearer. Such was the case in July, when the company announced it was in advanced talks to dispose of a stake in one of its investee companies, mLED Limited. The share price doubled, and though it came off the boil after the sales was confirmed in September, the shares are still up a very handy 77% over the last year. The group has a 1.25% direct holding and 3.75% stake held through subsidiary Strathclyde Investment Fund in mLED. Proceeds from the sale were £399,000 in cash compared to a book value of £96,000. The money went in the kitty, to invest in more promising technology companies. Talking of which … shares were on the rise again in January 2017 as the company took a 47% stake in Gyrometric Systems Limited, an engineering firm using technology developed at Nottingham Trent University. Gyrometric provides monitoring technology that measures the performance of drive shafts in a wide variety of applications. In effect, the technology tunes the devices, enabling them to operate at maximum efficiency, thereby saving energy, maintenance and capital costs. The large stake taken by Braveheart represents a continuation of the change of strategy by Braveheart, with the company gaining in confidence and backing its judgement more heavily. Not that Gyrometric seems like a particularly risky investment. Braveheart said Gyrometric already has established sales partners in Germany and Asia on which it will now build and expects to break-even in 2017. Selling a stake in a company provides a nice occasional bonus for the company, but the steady income is provided by its wholly-owned subsidiary, Viking Fund Managers. Viking's main fund management income comes from the Finance Yorkshire Equity Fund contract, but it also provides specialist fund management services to other funds that are in 'run-out' mode. This specialised management work tends to generate enhanced fees in excess of standard fund management fees due to the intensive nature of this work. The emphasis for the FYEF is now on portfolio management rather than in seeking new investments and the unit is seeking to win the management contracts for further funds. Viking was recently awarded an additional sum of £2 million of new capital to invest through the existing FYED contract, which means that the investment phase of this contract has been extended into 2017 – March, to be precise. Once this extended investment phase of the contract is completed, Viking will concentrate on realising fund investments with this part of the management contract expected to be completed during 2019. Viking was not successful in winning a fund management contract for the initial phase of the new Northern Powerhouse Investment Fund initiative; however it continues to work with a number of third parties with a view to gaining new fund management contracts. Interim results for the whole group released in October revealed costs were cut in half from a year earlier, which meant pre-tax profits for the six months to September 30 of £475,000 were the largest since the company floated more than eight years ago. They were achieved on revenues of £562,000 and compared with a loss in the comparable period last year of just over £1mln. Overheads fell from £868,000 to £435,000. The comp recently took on 33% of Paraytec, a York-based scientific instruments specialist, and 28% of Kirkstall, which makes equipment for cell tissue labs. Both companies are performing well, either meeting or exceeding internal targets set for them. Sales have now begun of Paraytec's ActiPix D200 system, which was recently introduced into the global pharmaceutical market, Braveheart revealed. Sirius Analytical, one of the first ActiPix licensees, has successfully launched a new drug dissolution imager, incorporating ActiPix technology. It has already met with strong interest from global research laboratories that are interested in licensing the ActiPix wizardry, Braveheart said. The royalties generated from such licences are expected to comprise the majority of Paraytec's future income. Meanwhile, sales of Kirkstall’s 'organ-on-a-chip` system, Quasi Vivo, are ahead of forecast. Research group Research and Markets estimates that the global `organ-on-a-chip` market is poised to grow at a compound annual growth rate of around 69% over the next decade to reach about US$6.13 billion by 2025.
Read Full Thread
Follow
Reply
09/2/2012
11:08		samuelchristo: Good afternoon all - I posted this on another thread: If I may I'd like to bring people's attention to Braveheart Investment Group (BRH). I feel the stock is now highly undervalued with a sub £2 million market cap. They have a NAV of 28p with a current share price of 10p. They have around £800,000 cash. They are invested in 23 quality companies who they will work each towards a profitable exit. I feel the share-price will quickly double and more during 2012. There will be plenty of newsflow due to the number of maturing companies they are working toward IPOs on. The chart isn't pretty but I feel this is due a bounce very soon. I have set up a new thread http://uk.advfn.com/cmn/fbb/thread.php3?id=26950477 with further information and links to their 23 investments. All are welcome. This is all my opinion and not intended to be investment advice. Thanks for your time. SC
Read Full Thread
Follow
Reply
Braveheart Investment share price data is direct from the London Stock Exchange
Your Recent History
LSE
BRH
Braveheart..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190723 12:10:06